{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT04338581: Phase 2 Interventional Active, not recruiting Vitiligo
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04701164: Phase 3 Interventional Completed Guillain-Barre Syndrome
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03486067: Phase 1 Interventional Active, not recruiting Multiple Myeloma
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01025206: Phase 1 Interventional Completed Multiple Myeloma
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04680637: Phase 2 Interventional Terminated Active Systemic Lupus Erythematosus
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04505137: Phase 1 Interventional Completed Pulmonary Arterial Hypertension
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:dovanvetmab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04380805: Phase 2 Interventional Completed Recurrent Cervical Cancer
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00003431: Phase 1 Interventional Completed Colorectal Cancer
(1998)
Source URL:
Class:
PROTEIN
